Table 1.
Baseline characteristics of the participants.
| Variables | AF (n = 1,028) | no-AF (n = 8,590) | P-value |
|---|---|---|---|
| Male (n/%) | 546 (53.1%) | 4,186 (48.7%) | 0.008 |
| Age (year) | 69.51 ± 9.20 | 66.30 ± 10.49 | <0.001 |
| Blood pressure readings | |||
| SBP (mm Hg) | 141.54 ± 19.50 | 146.29 ± 20.96 | <0.001 |
| DBP (mm Hg) | 82.65 ± 13.31 | 82.90 ± 12.81 | 0.566 |
| DM (n/%) | 264 (25.7%) | 2,502 (29.1%) | 0.021 |
| Dyslipidemia (n/%) | 793 (77.1%) | 7,078 (82.4%) | <0.001 |
| Lipid panel | |||
| TC (mg/dL) | 179.67 ± 40.27 | 186.28 ± 42.50 | <0.001 |
| TG (mg/dL) | 132.70 ± 74.56 | 149.18 ± 102.96 | <0.001 |
| HDL (mg/dL) | 47.25 ± 10.47 | 47.25 ± 11.24 | 0.977 |
| LDL (mg/dL) | 104.96 ± 28.97 | 104.97 ± 30.24 | 0.995 |
| Smoking (n/%) | 219 (21.6%) | 1,989 (24.6%) | 0.037 |
| Alcohol (n/%) | 145 (14.6%) | 1,242 (15.7%) | 0.351 |
| SUA (mol/L) | 356.59 ± 90.99 | 340.73 ± 89.63 | <0.001 |
| Scr (umol/L) | 75.24 ± 42.02 | 70.59 ± 35.85 | <0.001 |
| LAEDD (mm) | 39.57 ± 5.05 | 36.58 ± 3.42 | <0.001 |
| Antihypertensive agent | |||
| ACEI/ARB (n/%) | 569 (55.4%) | 4,779 (55.6%) | 0.862 |
| β-blocker (n/%) | 675 (65.7%) | 4,211 (49.0%) | <0.001 |
| CCB (n/%) | 625 (60.8%) | 5,490 (63.9%) | 0.500 |
| Statin (n/%) | 719 (69.9%) | 6,567 (76.4%) | <0.001 |
| Diuretic (n/%) | 179 (17.45) | 1,197 (13.9%) | 0.003 |
AF, Atrial fibrillation; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; DM, Diabetes mellitus; TC, Total Cholesterol TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SUA, Serum uric acid; Scr, Serum creatinine; LAEDD, Left atrial end-diastolic diameter; ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, angiotensin-converting enzyme receptor blockers; and CCB, Calcium channel blockers.